Who Owns Ultragenyx Pharmaceutical Stock?
NASDAQ: RAREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 112.48%
- Institutions (% of float)
- 116.49%
- Held by insiders
- 3.44%
- Institutional holders
- 433
- Institutions 96.6%
- Insiders 3.4%
- Public and other 0.0%
Who owns Ultragenyx Pharmaceutical stock?
Institutional investors own about 112.5% of Ultragenyx Pharmaceutical's shares, spread across 433 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 3.44% of RARE.
The largest institutional holders are Blackrock Inc. (10.81%), RTW Investments LP (7.91%) and Vanguard Portfolio Management LLC (6.89%). Together, the top 10 institutions control 55.6% of shares outstanding. In their latest filings, 9 of the top 10 institutions increased their RARE positions and 1 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of RARE
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Blackrock Inc. | 10.65M | 10.81% | +46.0% |
| RTW Investments LP | 7.80M | 7.91% | +113.7% |
| Vanguard Portfolio Management LLC | 6.79M | 6.89% | +26.1% |
| AQR Capital Management, LLC | 6.56M | 6.65% | +43.3% |
| State Street Corporation | 6.16M | 6.25% | +22.6% |
| Vanguard Capital Management LLC | 4.30M | 4.36% | +2.5% |
| Two Sigma Investments, LP | 3.62M | 3.67% | +64.2% |
| Sands Capital Management, LLC | 3.16M | 3.20% | -1.8% |
| Jacobs Levy Equity Management, Inc. | 2.94M | 2.98% | +105.4% |
| Frontier Capital Management Company LLC | 2.85M | 2.89% | +30.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of RARE
| Fund | Shares | % Held |
|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 3.86M | 3.92% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.99M | 3.03% |
| iShares Trust-iShares Russell 2000 ETF | 2.46M | 2.50% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.14M | 2.18% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.24M | 1.26% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.13M | 1.14% |
| VANGUARD HORIZON FUNDS-Vanguard Strategic Equity Fund | 1.07M | 1.09% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.06M | 1.07% |
| AQR Funds-AQR Long-Short Equity Fund | 914.72K | 0.93% |
| Vanguard Explorer Fund | 821.99K | 0.83% |
Frequently asked questions
Who is the largest shareholder of Ultragenyx Pharmaceutical?
Blackrock Inc. is the largest institutional shareholder of RARE, owning 10.81% of shares outstanding (10.65M shares) as of its latest 13F filing.
What percentage of Ultragenyx Pharmaceutical is owned by institutions?
Institutions own about 112.5% of RARE shares and 116.5% of the public float.
How much of Ultragenyx Pharmaceutical do insiders own?
Insiders, such as officers and directors, own about 3.44% of RARE shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.